Transpact Enterprises Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003273,
    "name": "Transpact Enter.",
    "stock_name": "Transpact Enter.",
    "full_name": "Transpact Enterprises Ltd",
    "name_url": "stocks-analysis/transpact-enter",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "132.80",
    "chg": -14.75,
    "chgp": "-10.0%",
    "dir": -1,
    "prev_price": "147.55",
    "mcapval": "6.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 542765,
    "symbol": "",
    "ind_name": "Capital Markets",
    "ind_code": 26,
    "indexname": "",
    "isin": "INE06YD01010",
    "curr_date": "Dec 16",
    "curr_time": "",
    "bse_nse_vol": 7000,
    "exc_status": "Active",
    "traded_date": "Dec 16, 2025",
    "traded_date_str": "2025 12 16",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/transpact-enter-1003273-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Transpact Enter.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-transpact-enter-3703897",
        "imagepath": "",
        "date": "2025-11-15 00:17:37",
        "description": "Answer:\nThe historical performance of Transpact Enter shows a fluctuating trend in its financial metrics over the years, with a notable improvement in recent periods.\n\nBreakdown:\nTranspact Enter's net sales increased to 0.08 Cr in March 2025 from 0.00 Cr in March 2024 and March 2023, indicating a recovery from previous years where sales were either minimal or non-existent. The total operating income also rose to 0.08 Cr in March 2025, up from 0.00 Cr in the prior two years. The company reported an operating profit of 0.04 Cr in March 2025, a significant turnaround from the losses recorded in previous years, such as -0.06 Cr in March 2024 and -0.14 Cr in March 2023. Profit after tax showed a positive shift to 0.01 Cr in March 2025, compared to losses in the preceding years. The total assets of the company were 0.70 Cr in March 2025, a slight increase from 0.66 Cr in March 2024, while total liabilities also r..."
      },
      {
        "title": "When is the next results date for Transpact Enter.?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-transpact-enter-3691214",
        "imagepath": "",
        "date": "2025-11-11 23:20:01",
        "description": "Transpact Enter. will declare its results on 14 November 2025...."
      },
      {
        "title": "Is Transpact Enter. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-transpact-enter-overvalued-or-undervalued-3642563",
        "imagepath": "",
        "date": "2025-10-24 08:13:07",
        "description": "As of 23 October 2025, the valuation grade for Transpact Enter. has moved from risky to very expensive. The company is currently overvalued, as indicated by its exceptionally high PE ratio of 913.07 and a price to book value of 9.13. Additionally, the EV to EBITDA stands at 9.12, which, while not extreme compared to the PE ratio, still suggests a lack of profitability relative to its valuation.\n\nIn comparison to its peers, Transpact Enter. shows stark contrasts; for instance, Poly Medicure has a PE of 54.6 and an EV to EBITDA of 40.61, while Blue Jet Health has a PE of 31.47 and an EV to EBITDA of 24.20. Both peers are also classified as very expensive, but their ratios are significantly lower than those of Transpact Enter., reinforcing the notion of overvaluation. Despite a solid performance against the Sensex over the past year, with a return of 14.72% compared to the Sensex's 5.59%, the current valuation..."
      },
      {
        "title": "Is Transpact Enter. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-transpact-enter-overvalued-or-undervalued-3602112",
        "imagepath": "",
        "date": "2025-10-08 08:03:46",
        "description": "As of 7 October 2025, the valuation grade for Transpact Enter. has moved from risky to very expensive. This indicates a significant shift in perception regarding the company's valuation. Based on the analysis, Transpact Enter. is currently overvalued. The company's PE ratio stands at 9.13, while its EV to EBITDA ratio is also at 9.12, which is notably high compared to its peers. Furthermore, the ROE is only 1.00%, suggesting limited profitability relative to its equity.\n\nIn comparison to its peers, Transpact Enter. shows stark contrasts; for instance, Poly Medicure has a PE ratio of 52.62, and Blue Jet Health stands at 32.53, both indicating much higher valuations based on earnings. The PEG ratio for Transpact Enter. is 0.00, which further emphasizes its lack of growth potential relative to its price. While the company's recent stock performance has outpaced the Sensex, with a 1-year return of 27.93% compar..."
      }
    ],
    "total": 15,
    "sid": "1003273",
    "stock_news_url": "https://www.marketsmojo.com/news/transpact-enterprises-1003273"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For Adoption Of Unaudited Financial Results For The Half Year Ended September 30 2025.",
      "datetime": "14-Nov-2025",
      "details": "Board Meeting Outcome for adoption of Unaudited Financial Results for the half year ended September 30 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting To Be Held On Friday 14Th November 2025 At 04:00 P.M.",
      "datetime": "10-Nov-2025",
      "details": "Transpact Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve 1. To consider and approve the Unaudited Financial Results for the half year ended on September 30 2025. 2. Any other agenda with the permission of Chairman of the meeting.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "13-Oct-2025",
      "details": "Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30th September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Transpact Enter.?

2025-11-15 00:17:37

Answer: The historical performance of Transpact Enter shows a fluctuating trend in its financial metrics over the years, with a notable improvement in recent periods. Breakdown: Transpact Enter's net sales increased to 0.08 Cr in March 2025 from 0.00 Cr in March 2024 and March 2023, indicating a recovery from previous years where sales were either minimal or non-existent. The total operating income also rose to 0.08 Cr in March 2025, up from 0.00 Cr in the prior two years. The company reported an operating profit of 0.04 Cr in March 2025, a significant turnaround from the losses recorded in previous years, such as -0.06 Cr in March 2024 and -0.14 Cr in March 2023. Profit after tax showed a positive shift to 0.01 Cr in March 2025, compared to losses in the preceding years. The total assets of the company were 0.70 Cr in March 2025, a slight increase from 0.66 Cr in March 2024, while total liabilities also r...

When is the next results date for Transpact Enter.?

2025-11-11 23:20:01

Transpact Enter. will declare its results on 14 November 2025....

Is Transpact Enter. overvalued or undervalued?

2025-10-24 08:13:07

As of 23 October 2025, the valuation grade for Transpact Enter. has moved from risky to very expensive. The company is currently overvalued, as indicated by its exceptionally high PE ratio of 913.07 and a price to book value of 9.13. Additionally, the EV to EBITDA stands at 9.12, which, while not extreme compared to the PE ratio, still suggests a lack of profitability relative to its valuation. In comparison to its peers, Transpact Enter. shows stark contrasts; for instance, Poly Medicure has a PE of 54.6 and an EV to EBITDA of 40.61, while Blue Jet Health has a PE of 31.47 and an EV to EBITDA of 24.20. Both peers are also classified as very expensive, but their ratios are significantly lower than those of Transpact Enter., reinforcing the notion of overvaluation. Despite a solid performance against the Sensex over the past year, with a return of 14.72% compared to the Sensex's 5.59%, the current valuation...

Is Transpact Enter. overvalued or undervalued?

2025-10-08 08:03:46

As of 7 October 2025, the valuation grade for Transpact Enter. has moved from risky to very expensive. This indicates a significant shift in perception regarding the company's valuation. Based on the analysis, Transpact Enter. is currently overvalued. The company's PE ratio stands at 9.13, while its EV to EBITDA ratio is also at 9.12, which is notably high compared to its peers. Furthermore, the ROE is only 1.00%, suggesting limited profitability relative to its equity. In comparison to its peers, Transpact Enter. shows stark contrasts; for instance, Poly Medicure has a PE ratio of 52.62, and Blue Jet Health stands at 32.53, both indicating much higher valuations based on earnings. The PEG ratio for Transpact Enter. is 0.00, which further emphasizes its lack of growth potential relative to its price. While the company's recent stock performance has outpaced the Sensex, with a 1-year return of 27.93% compar...

View All News